TITLE

FDA actions

PUB. DATE
April 2011
SOURCE
Clinical Cardiology Alert;Apr2011 Pharmacology, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The articles offers news briefs related to the U.S. Food and Drug Administration (FDA). A warning has been issued concerning the use of terbutaline for prevention or prolonged treatment of preterm labor in pregnant women. The FDA has approved Spinosad, a treatment for head lice. A warning regarding dronedarone (Multaq), a drug used to prevent atrial fibrillation/flutter, has been issued.
ACCESSION #
60805769

 

Related Articles

  • FDA actions. Elliott, William T. // Critical Care Alert;Apr2011 Pharmacology, p2 

    The article offers updates on actions taken by the U.S. Food and Drug Administration (FDA). The FDA has added a Boxed Warning and Contraindication to the labeling of terbutaline warning against its uses for prevention or prolonged treatment of preterm labor in pregnant women. A drug safety alert...

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Apr2011 Clinical Brief, p2 

    The article reports on the drug approvals by the U.S. Food and Drug Administration (FDA). The FDA approved Spinosad for the treatment of head lice. The FDA issued an alert on the safety of the drug dronedarone (Multaq) approved for the prevention of atrial fibrillation because it has been...

  • FDA actions. Elliott, William T. // Primary Care Reports;Feb2012 Pharmacology Watch, p2 

    The article discusses several FDA actions, including approval to generic atorvastatin (Lipitor) by Ranbaxy Laboratories and Prevnar 13 by Wyeth Pharmaceuticals; and the requirement for revised labeling of Dronedarone (Multaq), for patients with permanent atrial fibrillation (AF).

  • FDA OKs new product to prevent osteoporosis.  // Drug Topics;6/21/2004, Vol. 148 Issue 12, p14 

    This article reports on the U.S. Food and Drug Administration approval of Menostar for the prevention of postmenopausal osteoporosis. In clinical trials, the safety and tolerability profile of Menostar was comparable to that of placebo.

  • Formulary Drug Reviews - Spinosad 0.9% Topical Suspension. Cada, Dennis J.; Levien, Terri L.; Baker, Danial E. // Hospital Pharmacy;Jun2011, Vol. 46 Issue 6, p436 

    The article offers information on Spinosad 0.9% topical suspension, a topical head lice infestation treatment. It states that spinosad is made from fermented Saccharopolyspora spinosa, an actinomycetes bacterium derived from soil, and does not involve any extensive management program for lice....

  • FDA actions. Elliott, William T. // Primary Care Reports;Jun2013 Pharmacology Watch, p2 

    The article focuses on the recent actions taken by the Food and Drug Administration (FDA). It is mentioned that the FDA has approved the relabelling of newer tamper-proof oxycodone (OxyContin) drugs to reduce its abuse. It states that a fixed combination of doxylamine succinate and pyridoxine...

  • Current FDA-Related Drug Information - New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; Agents Pending FDA Approval; New Drug/Biologics License Applications Filed by Manufacturer; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes or 'Dear Health Professional' Letters Related to Safety Baker, Danial E. // Hospital Pharmacy;Jul2011, Vol. 46 Issue 7, p531 

    Several tables related to drugs are presented which include the new drugs approved by the U.S. Food and Drug Administration (FDA), new dosage forms and indications approved by FDA, and new drug or biologics license applications filed by manufacturer.

  • Cephalon's Nuvigil Gets Nod; Label Change, No New Trials. Osborne, Randall // BioWorld Today;4/3/2007, Vol. 18 Issue 64, p1 

    The article reports on the approval by the U.S. Food & Drug Administration of a drug called Nuvigil from Cephalon Inc. Nuvigil is designed to improve wakefulness in patients suffering from excessive sleepiness associated with narcolepsy and sleep disorders. Cephalon is required to add bold-face...

  • FDA actions. Elliott, William T. // Primary Care Reports;Dec2010 Pharmacology, p2 

    This section offers news briefs on actions taken by the U.S. Food and Drug Administration (FDA) as of December 2010. The FDA has approved fingolimod, an oral drug for the treatment of relapsing forms of multiple sclerosis. The agency has also approved dabigatran, a drug for the prevention of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics